Abbisko Cayman Limited (HKEX:2256) Filings

Abbisko Cayman Limited

Filings

FilingDateTypeFiled with
VOLUNTARY ANNOUNCEMENT - Abbisko Therapeutics Presents Preclinical Findings on Novel Selective CDK4 Inhibitor ABSK192 in Single-Agent and Combination Studies at 2026 ENANov 18, 2026Operations updateHKEX
VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING OF THE COMPANY BY THE FOUNDER, THE EXECUTIVE DIRECTOR, THE CHIEF EXECUTIVE OFFICER AND THE CHAIRMAN OF THE BOARD OF THE COMPANYNov 11, 2026Ownership change noticeHKEX
INSIDE INFORMATION - PIMJETMI (pimicotinib) Receive U.S. FDA Approval for TGCTNov 10, 2026Operations updateHKEX
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026Nov 2, 2026Monthly returnHKEX
CHANGE OF COMPANY NAMENov 1, 2026Other filingsHKEX
Next Day Disclosure ReturnsOct 30, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnsOct 29, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnsOct 27, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnsOct 23, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnsOct 21, 2026Next day disclosure returnHKEX
VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS' LAVENGRATINIB (ABSK061) FOR THE TREATMENT OF ACHONDROPLASIA GRANTED ORPHAN DESIGNATION BY EMAOct 21, 2026Other filingsHKEX
Next Day Disclosure ReturnsOct 20, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnsOct 15, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnsOct 14, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnsOct 8, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnsOct 7, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnsOct 6, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnsOct 5, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnsOct 2, 2026Next day disclosure returnHKEX
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026Oct 2, 2026Monthly returnHKEX
Next Day Disclosure ReturnsSep 29, 2026Next day disclosure returnHKEX
Next Day Disclosure ReturnsSep 28, 2026Next day disclosure returnHKEX
2026 INTERIM REPORTSep 22, 2026Interim reportHKEX
VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS ANNOUNCES POSITIVE PRELIMINARY PHASE II RESULTS WITH LAVENGRATINIB (ABSK061) FOR THE TREATMENT OF ACHONDROPLASIASep 20, 2026ResultsHKEX
POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON SEPTEMBER 17, 2026Sep 17, 2026Meeting outcomeHKEX